2EyesVision, an innovative ophthalmology technology company, has announced the launch of a €1 million funding round with the support of Capital Cell — Europe’s leading alternative investment platform specialized in biotechnology and life sciences. Capital Cell currently has over 21,500 investors and has raised €135 million through 145 funding rounds since 2015.
Following a favorable evaluation by BioExpert Network (Capital Cell’s international network of experts), the company has opened a private fundraising phase. This stage is prioritized for premium investors who can access the opportunity under favorable valuation terms. The minimum investment ticket is €1,000, making it accessible to both small and large investors. Additionally, investors participating in this private phase will benefit from up to a 15% discount on the company’s final valuation, with the option to reserve their investment without the need for an immediate capital outlay.
2EyesVision has set a strategic goal of reaching €6 million in revenue and a positive EBITDA by 2028. To achieve this, the company plans to implement its recently launched SimVis Gekko2 technology in 500 clinics worldwide and establish strategic partnerships with intraocular lens manufacturers.
The technology developed by 2EyesVision — which has already been very well received in the market — allows patients to experience how their vision will be after cataract or presbyopia surgery. This helps improve communication with doctors, reduces uncertainty, and increases postoperative satisfaction. Currently, the SimVis technology is present in 19 countries, supported by over 25 scientific publications and an international Medical Advisory Board.
The backing of Capital Cell, Europe’s largest equity crowdfunding platform in the healthcare sector, has been key in driving this new growth phase for 2EyesVision. To date, €600,000 has already been committed by renowned investors such as Bullnet Capital and CDTI. The company aims to raise a total of €1 million during the last quarter of 2025, which will accelerate its international expansion and global product rollout.
Additionally, the company has secured a €300,000 loan from ENISA through its Growth program. These contributions strengthen the project’s financial position and highlight institutional investors’ confidence in 2EyesVision’s potential.
According to Carlos Dorronsoro, CEO of 2EyesVision: “The backing and support of a platform with Capital Cell’s expertise not only validates the strength of our value proposition but also opens the door to a wide range of investors eager to join this growth stage. Capital Cell’s proven track record, past successes, and network will be instrumental during this phase of our company’s development.”
About 2EyesVision
2EyesVision develops disruptive ophthalmology solutions focused on enhancing the patient experience and clinical decision-making process. Its innovative visual simulator, SimVis Gekko, allows patients to preview their post-surgery vision before undergoing presbyopia or cataract procedures. The new generation, SimVis Gekko2, includes a Pupil Monitoring System that improves clinical workflow integration through faster, more precise, and stable alignment. The company continues to develop new technologies that position it as a leading innovator in visual health.
Initially founded by scientists from CSIC in collaboration with leading engineers and ophthalmologists, 2EyesVision has been supported by ERC, CSIC, Comunidad de Madrid, the Ministry of Science and Innovation, EIT Health, Horizon 2020 (European Union), Bullnet Capital, Neotec-CDTI, Innvierte-CDTI, ENISA, and Luminate, a New York-based global optics and photonics investment fund.
About Capital Cell
Capital Cell is Europe’s leading crowdfunding platform for alternative investment in biotechnology and life sciences. Founded in 2015, it enables private and professional investors to participate in high-potential funding rounds, providing transparency, guidance, and access to carefully selected opportunities. The platform has supported more than 150 companies, connecting innovation, talent, and capital to accelerate the development of impactful medical and scientific solutions.
About the Investors
Bullnet Capital
Bullnet Capital is an independent Spanish venture capital firm focused on high-technology companies (software, electronics, semiconductors, photonics). Founded in 2002, it manages a total of €140 million across several investment vehicles. To date, Bullnet Capital has invested in thirty early-stage Spanish companies and continues to follow its investment philosophy of adding value and actively supporting portfolio companies.
www.bullnetcapital.com
Innvierte
Innvierte is an initiative aimed at promoting business innovation by supporting venture capital investment in technology-based or innovative companies. It operates through the closed-end investment company Innvierte Economía Sostenible SICC S.M.E., S.A., which is self-managed and supervised by the Spanish National Securities Market Commission (CNMV), with CDTI Innovación as its sole shareholder.
To date, CDTI Innovación has committed €2.847 billion across 63 investment vehicles, which have invested in over 632 companies. Through its co-investment line, it has directly invested €726 million in 191 companies.
Innvierte is part of the Spanish Strategy for Science, Technology, and Innovation 2021–2027, approved by the Council of Ministers in September 2020. This strategy sets out objectives and measures to boost the country’s R&D&I ecosystem and serves as one of the key pillars of Spain’s innovation policy.
CDTI Innovación
The Centre for Technological Development and Innovation (CDTI E.P.E.) is a public entity under the Ministry of Science, Innovation, and Universities, dedicated to promoting technological innovation within the business sector. Its mission is to enable Spanish companies to generate and transform scientific and technical knowledge into globally competitive, sustainable, and inclusive growth. In 2024, as part of a new strategic plan, CDTI provided more than €2.3 billion in funding to Spanish companies and startups.
cloud technology axon
The new fund aims to reach a size of €60 million and has been establ...
